Table 1 In vitro cytotoxicity (IC50, µM ± SE) of compounds 2–15 compared to doxorubicin, evaluated in HEPG2 and MCF7 human cancer cell lines. IC50 values were determined by 4-parameter nonlinear regression from pooled triplicate data across three independent experiments.

From: Synthesis, comprehensive in silico studies, and cytotoxicity evaluation of novel quinazolinone derivatives as potential anticancer agents

Compound

HEPG2 IC50 ± SE (µM)

MCF7 IC50 ± SE (µM)

Doxorubicin

4.50 ± 0.2

4.17 ± 0.2

2

56.14 ± 3.1

61.24 ± 3.5

3

8.96 ± 0.6

3.84 ± 0.2

4

68.32 ± 3.8

54.22 ± 3.2

5

6.90 ± 0.4

5.58 ± 0.3

6

38.12 ± 2.4

9.14 ± 0.7

7

63.57 ± 3.6

39.27 ± 2.4

8

10.48 ± 0.9

18.12 ± 1.4

9

52.18 ± 2.9

29.28 ± 2.1

10

13.09 ± 1.1

15.47 ± 1.2

11

83.60 ± 4.1

78.69 ± 4.0

12

27.73 ± 2.0

7.76 ± 0.5

13

19.38 ± 1.4

23.68 ± 1.8

14

32.56 ± 2.2

34.66 ± 2.3

15

75.51 ± 3.9

44.40 ± 2.6

  1. IC50 classification: 1–10 µM (very high), 11–20 µM (high), 21–50 µM (moderate), 51–100 µM (low), > 100 µM (non-cytotoxic).
Back to article page